Post normalisation of high growth months of April and May this year the average IPM growth from June to August this year stood at 15.2 % YoY : Ind-Ra reports
Ind-Ra expects IPM revenue to grow over 12% YoY in FY22
Domestic business was up 41.9% YoY and 27.7% QoQ
Price erosion, weak demand for acute portfolio and low ANDA approvals in the US weighed on the performance of Indian pharma in Q1FY22. However, the scenario is expected to change in H2FY22 when new approvals and inspections resume
Demand normalisation post the second wave contributed to the steady growth
Subscribe To Our Newsletter & Stay Updated
